BioCryst Pharmaceuticals, Inc. (BCRX)
8.76
+0.08
(+0.92%)
USD |
NASDAQ |
Sep 21, 16:00
8.76
0.00 (0.00%)
After-Hours: 05:32
BioCryst Pharmaceuticals EPS Diluted (TTM) : -1.504 for June 30, 2026
EPS Diluted (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.504 |
| March 31, 2026 | -1.776 |
| December 31, 2025 | 1.203 |
| September 30, 2025 | -0.0473 |
| June 30, 2025 | -0.1738 |
| March 31, 2025 | -0.2583 |
| December 31, 2024 | -0.4301 |
| September 30, 2024 | -0.6074 |
| June 30, 2024 | -0.7302 |
| March 31, 2024 | -1.067 |
| December 31, 2023 | -1.178 |
| September 30, 2023 | -1.254 |
| June 30, 2023 | -1.292 |
| March 31, 2023 | -1.211 |
| December 31, 2022 | -1.330 |
| September 30, 2022 | -1.045 |
| June 30, 2022 | -1.144 |
| March 31, 2022 | -1.070 |
| December 31, 2021 | -1.031 |
| September 30, 2021 | -1.275 |
| June 30, 2021 | -1.208 |
| March 31, 2021 | -1.204 |
| December 31, 2020 | -1.087 |
| September 30, 2020 | -0.7641 |
| June 30, 2020 | -0.8434 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.9454 |
| December 31, 2019 | -0.9834 |
| September 30, 2019 | -1.213 |
| June 30, 2019 | -1.154 |
| March 31, 2019 | -1.002 |
| December 31, 2018 | -0.982 |
| September 30, 2018 | -0.9322 |
| June 30, 2018 | -0.8314 |
| March 31, 2018 | -0.8514 |
| December 31, 2017 | -0.7792 |
| September 30, 2017 | -0.6392 |
| June 30, 2017 | -0.6192 |
| March 31, 2017 | -0.6292 |
| December 31, 2016 | -0.75 |
| September 30, 2016 | -0.94 |
| June 30, 2016 | -0.98 |
| March 31, 2016 | -0.70 |
| December 31, 2015 | -0.60 |
| September 30, 2015 | -0.51 |
| June 30, 2015 | -0.43 |
| March 31, 2015 | -0.72 |
| December 31, 2014 | -0.68 |
| September 30, 2014 | -0.61 |
| June 30, 2014 | -0.63 |
| March 31, 2014 | -0.63 |
EPS Diluted (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (TTM) Benchmarks
| Amgen, Inc. | 16.10 |
| Halozyme Therapeutics, Inc. | 3.347 |
| Neurocrine Biosciences, Inc. | 6.826 |
| Vertex Pharmaceuticals, Inc. | 17.19 |
| Agenus, Inc. | 2.651 |